The utilization of chimeric antigen receptor (CAR) T-cell therapy to target cluster of differentiation (CD)19 in cancer immunotherapy has been a recent and significant advancement. Although this approach is highly specific and selective, it is not without complications. Therefore, a systematic review was conducted to assess the current state of positron emission tomography (PET) in evaluating the adverse effects induced by CAR T-cell therapy. A thorough search of relevant articles was performed in databases such as PubMed, Scopus, and Web of Science up until March 2024. Two reviewers independently selected articles and extracted data, which was then organized and categorized using Microsoft Excel. The risk of bias and methodological quality was assessed. In total, 18 articles were examined, involving a total of 753 patients, in this study. A wide range of utilities were analyzed, including predictive, correlative, and diagnostic utilities. While positive outcomes were observed in all the mentioned areas, quantitative analysis of the included studies was hindered by their heterogeneity and use of varying PET-derived parameters. This study offers a pioneering exploration of this promising field, with the goal of encouraging further and more focused research in upcoming clinical trials.
利用嵌合抗原受体（CAR）T细胞疗法靶向分化簇（CD）19进行癌症免疫治疗是近期一项重要进展。尽管该方法具有高度特异性和选择性，但仍存在并发症。因此，本研究通过系统综述评估正电子发射断层扫描（PET）在评估CAR T细胞疗法所致不良反应方面的应用现状。截至2024年3月，我们在PubMed、Scopus和Web of Science等数据库中全面检索了相关文献。由两名评审员独立筛选文献并提取数据，随后使用Microsoft Excel进行整理与分类。研究对偏倚风险和方法学质量进行了评估。本研究共纳入18篇文献，涉及753例患者。分析涵盖了预测性、相关性和诊断性等多方面应用价值。尽管上述领域均观察到积极结果，但由于纳入研究存在异质性且采用不同的PET衍生参数，阻碍了定量分析的开展。本研究对这一前景广阔的领域进行了开创性探索，旨在推动未来临床试验中开展更深入、更具针对性的研究。
FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review
肿瘤(癌症)患者之家